Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

BACKGROUND: Despite the incorporation of novel therapeutics, advanced triple negative breast cancer (TNBC) still represents a relevant clinical problem. Considering this, as well as the clinical efficacy of antibody-drug conjugates (ADCs), we aimed at identifying novel ADC targets that could be used...

Descripción completa

Detalles Bibliográficos
Autores principales: Montero, Juan Carlos, Calvo-Jiménez, Elisa, del Carmen, Sofía, Abad, Mar, Ocaña, Alberto, Pandiella, Atanasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941813/
https://www.ncbi.nlm.nih.gov/pubmed/35317825
http://dx.doi.org/10.1186/s13046-022-02330-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941813/
https://www.ncbi.nlm.nih.gov/pubmed/35317825
http://dx.doi.org/10.1186/s13046-022-02330-4

Ejemplares similares